Astrazeneca (AZN) said Saturday the full results from the Phase III trial showed Tezspire or tezepelumab, an asthma treatment jointly developed with Amgen (AMGN), led to significant reductions in nasal polyp severity, surgery requirements, and systemic corticosteroid use for patients with chronic rhinosinusitis with nasal polyps, compared with placebo.
At week 52, Tezspire improved the co-primary endpoints, reducing Nasal Polyp Score by -2.065 and nasal congestion by -1.028 compared with placebo, with benefits observed as early as weeks four and two respectively.
These findings were published in the New England Journal of Medicine and presented at the American Academy of Allergy Asthma & Immunology and World Allergy Organization Joint Congress in San Diego, California on Saturday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。